Oncology
Cancer touches the lives of millions of people around the world, and we know there is urgency to act. At Lantheus, we are dedicated to transforming cancer care by investigating next-generation radiodiagnostics and precision radiotherapeutics that enable both early and accurate detection and the ability to fight disease at the source.
The role of radiopharmaceuticals
in cancer care
Radiopharmaceuticals have played a vital role in cancer care for over a century, serving as a foundational diagnostic and therapeutic tool. Yet cancer continues to be a leading cause of death worldwide. At Lantheus, we understand that patients deserve more—more clarity when receiving a diagnosis and more options to treat disease with precision.
1 in 5 people globally will develop cancer in their lifetime1
people are diagnosed with cancer annually worldwide2
Oncology focus areas
We are advancing a diverse pipeline of potential next-generation radiodiagnostics and precision radiotherapeutics that, as potential theranostic pairs, could deliver best- or first-in-class opportunities in disease areas with high unmet need.
Prostate cancer
Prostate cancer is the second most common cancer in men worldwide.3 Lantheus is committed to following the science across multiple targets in our efforts to develop groundbreaking radioligand therapies and radiodiagnostic tracers, focusing on prostate-specific membrane antigens (PSMAs) and gastrin-releasing peptide receptors (GRPRs).
Neuroendocrine tumors (NETs)
NETs can arise in any organ, vary widely in form and behavior and can be rare and often difficult to diagnose.4 We’re developing a radiodiagnostic for NETs and taking a theranostic approach, exploring a potential radiodiagnostic and radiotherapeutic option for gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Other solid tumors
Our pipeline features several innovations for potentially diagnosing and treating a range of solid tumors like small cell lung cancer, glioblastoma, osteosarcoma, pancreatic ductal adenocarcinoma and lobular breast cancer.
A new frontier in molecular imaging and therapeutic options
Lantheus is committed to unlocking the full potential of radiopharmaceuticals, generating novel targets through our early development engine, advancing preclinical radiotheranostic programs and testing potential assets in cancers with high unmet need.
Molecular imaging for cancer
Imaging modalities like positron emission tomography (PET) have revolutionized cancer diagnosis, staging and monitoring. Low-dose radiotracers bind to select tissues,5 opening up the possibility for tailored treatment strategies and monitoring opportunities.
Precision cancer treatment
Radiotherapeutics have emerged as a powerful modality in cancer treatment. Radioligand therapies (RLTs) bind to antigens or receptors that overexpress on the surface of certain cancer cells, allowing radiotherapeutics to more specifically seek and destroy them while sparing healthy tissue.6
The emergence of theranostic solutions
Theranostics are a groundbreaking approach, combining a radiodiagnostic with a radiotherapeutic to selectively target and destroy cancer cells while minimizing damage to healthy tissues. They offer a promising solution for patients with hard-to-treat cancers.
REFERENCES
1. Global Cancer Burden Growing, Amidst Mounting Need for Services. World Health Organization. Published February 4, 2024. Accessed September 10, 2025. https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing–amidst-mounting-need-for-services 2. Worldwide Cancer Data. World Cancer Research Fund. Published 2025. Accessed November 14, 2025. https://www.wcrf.org/preventing-cancer/cancer-statistics/worldwide-cancer-data/ 3. Prostate Cancer Statistics. World Cancer Research Fund. Accessed September 10, 2025. https://www.wcrf.org/preventing-cancer/cancer-statistics/prostate-cancer-statistics/ 4. A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management. National Library of Medicine. Published August 5, 2023. Accessed May 21, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC10420169/ 5. Use of PET/CT Scanning in Cancer Patients: Technical and Practical Considerations. National Library of Medicine. Published October 18, 2005. Accessed May 21, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC1255942/ 6. Clinical Advances and Perspectives in Targeted Radionuclide Therapy. National Library of Medicine. Published June 14, 2023. Accessed May 21, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC10303056/
